ACR Convergence

An official publication of the ACR and the ARP serving rheumatologists and rheumatolgy professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • ACR Open Rheumatology
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Axial Spondyloarthritis

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

Thomas R. Collins  |  December 9, 2021

Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.

The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice

Mary Beth Nierengarten  |  December 2, 2021

Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.

Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis

Lara C. Pullen, PhD  |  November 16, 2021

Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.

Fiscal Year 2022 ICD-10-CM Codes Now in Effect

From the College  |  October 8, 2021

New and updated FY22 diagnosis codes became effective for encounters on or after Oct. 1, 2021, including key updates for Sjögren syndrome and non-radiographic axial spondyloarthritis.

Early & Long-Term Remission of Spondyloarthritis

Jason Liebowitz, MD  |  July 16, 2021

Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.

Cytokine Targets & Treatment Developments for Psoriatic Arthritis & Spondyloarthritis

Carina Stanton  |  March 15, 2021

ACR CONVERGENCE 2020—In recent years, a pathophysiological role for the interleukin (IL) 17/IL-23 axis in the development of psoriasis, enthesitis and inflammatory arthritis has been investigated in both rodent and human models. Clinical trials have demonstrated differential benefits for skin disease and joint disease in patients with psoriatic arthritis, axial spondyloarthritis (axSpA) and ankylosing spondylitis…

The Effects of IL-17A Inhibitors on the Microbiota

Vanessa Caceres  |  February 16, 2021

The use of an interleukin (IL) 17A inhibitor resulted in gut microbial dysbiosis and features of subclinical intestinal inflammation in a subgroup of psoriatic arthritis (PsA) and spondyloarthritis (SpA) patients, according to a multidisciplinary, collaborative study across several institutions published in Arthritis & Rheumatology.1 Understanding the downstream effects of these perturbations is an important step…

MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA

Lara C. Pullen, PhD  |  January 25, 2021

Three experts discuss the ins and outs of using magnetic resonance imaging to diagnose axial spondyloarthritis, particularly in individuals who lack clear clinical symptoms indicative of disease.

PG_Traveler / shutterstock.com

Case Report: Is It Reactive or IBD-Associated Arthritis?

Hanan Ibrahim, MD, Weixia Guo, MD, & Ayad Alkhatib, MD  |  January 19, 2021

Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2020

In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2000-2023 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences